Randomized, controlled trial of entecavir versus placebo in children with hepatitis B envelope antigen–positive chronic hepatitis B

Maureen M. Jonas, Mei‐Hwei Chang, Etienne Sokal, Kathleen B. Schwarz, Deirdre Kelly, Kyung Mo Kim, Simon C. Ling, Philip Rosenthal, Dumitru Oraseanu, Laurie Reynolds, Alexandra Thiry, Peter Ackerman – 29 July 2015 – This ongoing, randomized phase III study assesses the safety and efficacy of entecavir versus placebo in nucleos(t)ide‐naïve children (2 to <18 years) with hepatitis B envelope antigen (HBeAg)‐positive chronic hepatitis B (CHB). Blinded treatment was administered for a minimum of 48 weeks.

B cells expressing CD11b effectively inhibit CD4+ T‐cell responses and ameliorate experimental autoimmune hepatitis in mice

Xiaoming Liu, Xuechao Jiang, Ronghua Liu, Luman Wang, Tingting Qian, Yijie Zheng, Yuting Deng, Enyu Huang, Fengkai Xu, Ji‐Yang Wang, Yiwei Chu – 24 July 2015 – Increasing evidence in recent years has suggested that B cells act as a crucial regulator in autoimmune diseases. However, little is known about their role in autoimmune hepatitis (AIH) and the underlying regulatory mechanisms. In this study, we show that B cells ameliorated experimental AIH (EAH) by suppressing CD4+ T‐cell responses and that CD11b expression on B cells was required for the regulatory function of B cells.

Subscribe to